The type III TGF-β receptor regulates epithelial and cancer cell migration through β-arrestin2-mediated activation of Cdc42

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 20, 2009, Pages 8221-8226

  Mythreye, Karthikeyan ^a   Blobe, Gerard C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BETA ARRESTIN 2; PROTEIN CDC42; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3;

ARTICLE; CANCER CELL; CELL MIGRATION; CONTROLLED STUDY; CYTOSKELETON; EPITHELIUM CELL; FEMALE; HOMEOSTASIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ACTINS; ARRESTINS; CDC42 GTP-BINDING PROTEIN; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETON; EPITHELIAL CELLS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA;

EID: 66249141288     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0812879106     Document Type: Article

References (39)

1. Lauffenburger DA, Horwitz AF (1996) Cell migration: A physically integrated molecular process. Cell 84:359-369.
2. Raftopoulou M, Hall A (2004) Cell migration: Rho GTPases lead the way, Dev Biol 265:23-32.
3. Nobes CD, Hall A (1999) Rho GTPases control polarity, protrusion, and adhesion during cell movement, J Cell Biol 144:1235-1244.
4. Weiner OD (2002) Regulation of cell polarity during eukaryotic Chemotaxis: The chemotactic compass, Curr Opin Cell Biol 14:196-202.
5. Pankov R, et al. (2005) A Rac switch regulates random versusdirectionally persistent cell migration. J Cell Biol 170:793-802.
6. Wang XF, et al. (1991) Expression cloning and characterization of the TGF-beta type III receptor. Cell 67:797-805.
7. Lopez-Casillas F, et al. (1991) Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system, Cell 67:785-795.
8. Lopez-Casillas F, Wrana JL, Massague J (1993) Betaglycan presents ligand to the TGF beta signaling receptor. Cell 73:1435-1444.
9. Lewis KA et al. (2000) Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 404:411-414.
10. Stenvers KL, et al. (2003) Heart and liver defects and reduced transforming growth factor beta2 sensitivity In transforming growth factor beta type III receptor-deficient embryos. Mol Cell Biol 23:4371-4385.
11. Brown CB, Boyer AS, Runyan RB, Barnett JV (1999) Requirement of type III TGFbeta receptor for endocardial cell transformation in the heart. Science 283:2080-2082.
12. Kirkbride KC, Townsend TA Bruinsma MW, Barnett JV, Blobe GC (2008) Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. J Biol Chem 283:7628-7637.
13. Deng X, Bellis S, Yan Z, Friedman E (1999) Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 In cells with nonfunctional TGFbeta receptor type III. Cell Growth Differ 10:11-18.
14. Blobe GC, et al. (2001) Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor In regulating transforming growth factor beta signaling. J Biol Chem 276:24627-24637.
15. Blobe GC, Liu X, Fang SJ, How T, Lodish HF (2001) A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling, Functional modulation of type III TGF-beta receptor expression through Interaction with the PDZ domain protein, GIPC. J Biol Chem 276:39608-39617.
16. Chen W, et al. (2003) Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of Its signaling, Science 301:1394-1397.
17. Dong M, et al. (2007) The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest 117:206-217.
18. Hempel N, et al. (2007) Loss of betaglycan expression In ovarian cancer: Role in motility and invasion. Cancer Res 67:5231-5238.
19. Turley RS, et al. (2007) The type III transforming growth factor-beta receptor as a novel tumor suppressor gene In prostate cancer. Cancer Res 67:1090-1098.
20. Finger EC, et al. (2008) TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorlgenicity. Carcinogenesis 29:528-535.
21. Gordon KJ, Dong M, Chislock EM, Fields TA Blobe GC (2008) Loss of type III transforming growth factor beta receptor expression increases motility and Invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis 29:252-262.
22. Partin AW, Schoeniger JS, Mohler JL, Coffey DS (1989) Fourier analysis of cell motility: Correlation of motility with metastatic potential. Proc Natl Acad Sci USA 86:1254-1258.
23. Elliott RL, Blobe GC (2005) Role of transforming growth factor Beta In human cancer. J Clin Oncol 23:2078-2093.
24. Rodriguez GC, et al. (2001) Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol 80:245-253.
25. Etlenne-Mannevllle S, Hall A (2002) Rho GTPases in cell biology, Nature 420:629-635.
26. Wu X, Kodama A, Fuchs E (2008) ACF7 regulates cytoskeletal-focal adhesion dynamics and migration and has ATPase activity. Cell 135:137-148.
27. Glasgow JE, Daniele RP (1994) Role of microtubules in random cell migration: Stabilization of cell polarity. Cell Motil Cytoskeleton 27:88-96.
28. Lo CM, et al. (2004) Nonmuscle myosin IIb is involved in the guidance of fibroblast migration. Mol Biol Cell 15:982-989.
29. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL (2002) p38 mitogen-activated protein kinase Is required for TGFbeta-medlated fibroblastic transdifferentiation and cell migration. J Cell Sci 115:3193-3206.
30. Etienne-Manneville S, Hall A (2003) Cdc42 regulates GSK-3beta and adenomatous polyposis coll to control cell polarity, Nature 421:753-756.
31. Edlund S, Landstrom M, Heldin CH, Aspenstrom P (2002) Transforming growth factorbeta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 13:902-914.
32. Bayless KJ, Davis G E (2002) The Cdc42 and Rac1 GTPases are required for capillary lumen formation in three-dimensional extracellular matrices. J Cell Sci 115:1123-1136.
33. Hall A (1998) RhoGTPases and the actin cytoskeleton, Science 23:509-514.
34. Waite KA Eng C (2003) From developmental disorder to heritable cancer: It's all in the BMP/TGF-beta family. Nat Rev Genet 4:763-773.
35. Copland JA et al. (2003) Genomic profiling identifies alterations In TGFbeta signaling through loss of TGFbeta receptor expression In human renal cell carcinogenesis and progression. Oncogene 22:8053-8062.
36. DeFea KA (2007) Stop that cell I Beta-arrestin-dependent chemotaxis: A tale of localized actin assembly and receptor desensitization. Annu Rev Physiol 69:535560.
37. Kirkbride KC, Ray BN, Blobe GC (2005) Cell-surface co-receptors: Emerging roles in signaling and human disease, Trends Biochem Sci 30:611-621.
38. Ruoslahtl E, Yamaguchi Y (1991) Proteoglycans as modulators of growth factor activities, Cell 64:867-869.
39. Sahal E, Olson MF, Marshall CJ (2001) Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J 20:755-766.